CLCN3, chloride voltage-gated channel 3, 1182

N. diseases: 67; N. variants: 2
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Secondary malignant neoplasm of lymph node
0.010 Biomarker disease BEFREE Furthermore, higher expression of CLC-3 was correlated with deeper tumor invasion (P = 0.006) and increased lymph node metastasis (P = 0.016), and knockdown of CLC-3 inhibited cell proliferation and migration in vitro. 30217218 2018
CUI: C0947751
Disease: Vascular inflammations
Vascular inflammations
0.020 Biomarker phenotype BEFREE Furthermore, TNFα-induced vascular inflammation and neutrophil infiltration into the lung and liver were obviously attenuated in ClC-3 knockout mice (P<0.01; n=7). 23006728 2012
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.110 GeneticVariation disease GWASCAT Genome-wide association analysis identifies 30 new susceptibility loci for schizophrenia. 28991256 2017
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.110 GeneticVariation disease GWASCAT Genome-Wide Association Study Detected Novel Susceptibility Genes for Schizophrenia and Shared Trans-Populations/Diseases Genetic Effect. 30285260 2019
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.110 GeneticVariation disease GWASCAT Genome-wide association study of schizophrenia in Ashkenazi Jews. 26198764 2015
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.010 Biomarker disease BEFREE Here, we define the following intracellular mechanisms regulated by 1,25D3 that are associated with recovery of phagocytosis and consistent with the selectivity of BDC: 1) 1,25D3 potentiates a 4,4-diisothiocyanostilbene-2,2-disulfonic acid-sensitive chloride channel (i.e., ClC-3) currents in both Type I and II AD macrophages, but curcumin only potentiates the currents in Type I cells; 2) 1,25D3 is particularly effective in upregulating ClC-3 mRNA expression in Type II peripheral blood mononuclear cells (PBMCs) while both 1,25D3 and the BDC analog, C180, upregulate VDR mRNA, repressed by Aβ42 in Type II PBMCs; and 3) 1,25D3-induced Aβ42 phagocytosis is attenuated by the calcium-dependent ClC-3 blocker, inositol 3,4,5,6-tetraphosphate (IP4), in both AD Types and by the MEK1/2 inhibitor U0126 only in Type II macrophages. 22207005 2012
CUI: C0002726
Disease: Amyloidosis
Amyloidosis
0.010 Biomarker disease BEFREE Here, we define the following intracellular mechanisms regulated by 1,25D3 that are associated with recovery of phagocytosis and consistent with the selectivity of BDC: 1) 1,25D3 potentiates a 4,4-diisothiocyanostilbene-2,2-disulfonic acid-sensitive chloride channel (i.e., ClC-3) currents in both Type I and II AD macrophages, but curcumin only potentiates the currents in Type I cells; 2) 1,25D3 is particularly effective in upregulating ClC-3 mRNA expression in Type II peripheral blood mononuclear cells (PBMCs) while both 1,25D3 and the BDC analog, C180, upregulate VDR mRNA, repressed by Aβ42 in Type II PBMCs; and 3) 1,25D3-induced Aβ42 phagocytosis is attenuated by the calcium-dependent ClC-3 blocker, inositol 3,4,5,6-tetraphosphate (IP4), in both AD Types and by the MEK1/2 inhibitor U0126 only in Type II macrophages. 22207005 2012
CUI: C2931822
Disease: Nasopharyngeal carcinoma
Nasopharyngeal carcinoma
0.400 Biomarker disease BEFREE Here, we showed that the involvement of ClC-3 chloride channel in the selective cytotoxicity of DSF/Cu<sup>2+</sup> in the poorly-differentiated nasopharyngeal carcinoma. 31606620 2019
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.040 AlteredExpression group BEFREE High-grade expression of cytoplasmic ClC-3 predicted poor survival in cancer patients. 25537517 2015
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.040 AlteredExpression group BEFREE High-grade expression of cytoplasmic ClC-3 predicted poor survival in cancer patients. 25537517 2015
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.030 Biomarker disease BEFREE In conclusion, we demonstrated that ClC-3 can arrest the cell cycle at the G1 phase to inhibit cell proliferation, suggesting that ClC-3 has the potential to be a novel target for HCC therapy and potentially improve the prognosis of HCC patients. 29749557 2018
CUI: C0028754
Disease: Obesity
Obesity
0.010 Biomarker disease BEFREE In the present study we investigated the role of Clcn3 in high-fat diet (HFD)-induced obesity and ATM inflammation. 31165783 2019
CUI: C0017638
Disease: Glioma
Glioma
0.340 Biomarker disease BEFREE In the present study we provide several lines of evidence that glioma Cl- currents are primarily mediated by ClC-2 and ClC-3, two genes that belong to the ClC superfamily. 12843258 2003
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.050 Biomarker disease BEFREE In the present study, we showed the involvement of intracellular organelle ClC-3 Cl<sup>-</sup> /H<sup>+</sup> transporter in HER2 transcription in breast cancer MDA-MB-453 cells. 29949674 2018
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.050 Biomarker disease BEFREE In the present study, we showed the involvement of intracellular organelle ClC-3 Cl<sup>-</sup> /H<sup>+</sup> transporter in HER2 transcription in breast cancer MDA-MB-453 cells. 29949674 2018
CUI: C0302592
Disease: Cervix carcinoma
Cervix carcinoma
0.010 AlteredExpression disease BEFREE In this research, we explore the ClC-3 expression in cervical carcinoma and its underlying clinical significance, trying to illuminate ClC-3 probable function in the neoplasm malignant behavior, development and prognosis. 30636929 2019
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.040 Biomarker group BEFREE In this research, we explore the ClC-3 expression in cervical carcinoma and its underlying clinical significance, trying to illuminate ClC-3 probable function in the neoplasm malignant behavior, development and prognosis. 30636929 2019
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.040 Biomarker group BEFREE In this research, we explore the ClC-3 expression in cervical carcinoma and its underlying clinical significance, trying to illuminate ClC-3 probable function in the neoplasm malignant behavior, development and prognosis. 30636929 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.030 AlteredExpression disease BEFREE In this study, we have shown that heterologous expression of ClC-3 in either Chinese hamster ovary (CHO-K1) or human hepatoma (Huh-7) cells results in the formation of large, acidic vesicular structures within cells. 11997263 2002
CUI: C0023903
Disease: Liver neoplasms
Liver neoplasms
0.010 AlteredExpression group BEFREE In this study, we have shown that heterologous expression of ClC-3 in either Chinese hamster ovary (CHO-K1) or human hepatoma (Huh-7) cells results in the formation of large, acidic vesicular structures within cells. 11997263 2002
CUI: C0027796
Disease: Neuralgia
Neuralgia
0.010 Biomarker phenotype BEFREE Intrathecal Cltx to OVX and OVX + SNI rats was administered for 4 consecutive days (days 7-10 after SNI) to further determine the contribution of ClC-3 to neuropathic pain. 31787875 2019
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion
0.060 Biomarker phenotype BEFREE Mechanistic studies suggested that canonical TGF-β/Smad signaling pathway is involved in CLC-3-induced gastric cancer cells proliferation, migration and invasion. 29795988 2018
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.110 GeneticVariation disease GWASCAT Meta-analysis of GWAS of over 16,000 individuals with autism spectrum disorder highlights a novel locus at 10q24.32 and a significant overlap with schizophrenia. 28540026 2017
Child Development Disorders, Pervasive
0.100 GeneticVariation group GWASCAT Meta-analysis of GWAS of over 16,000 individuals with autism spectrum disorder highlights a novel locus at 10q24.32 and a significant overlap with schizophrenia. 28540026 2017
CUI: C2945695
Disease: Limb ischemia
Limb ischemia
0.010 Biomarker disease BEFREE Mice lacking of ClC-3 exhibited reduced blood flow recovery and neovascularization in ischemic muscles 7 and 14 days after hind limb ischemia. 31679624 2019